Premium
Perimenstrual Eletripan Prevents Menstrual Migraine: An Open‐Label Study
Author(s) -
Marcus Dawn A.,
Bernstein Cheryl D.,
Sullivan Erin A.,
Rudy Thomas E.
Publication year - 2010
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/j.1526-4610.2010.01628.x
Subject(s) - migraine , medicine , pharmacology
Objective.— To prospectively evaluate the efficacy of perimenstrual prophylaxis with eletriptan to reduce headaches in women identified with menstrual migraine (MM). Methods.— Female migraineurs self‐reporting a substantial relationship between migraine and menses were evaluated with 3 consecutive months of daily headache recording diaries. A relationship between menses and migraine was evaluated using International Classification of Headache Disorders (ICHD‐II) criteria and a probability model called Probability MM. Women prospectively diagnosed with ICHD‐II MM were treated for 3 consecutive months with perimenstrual eletriptan 20 mg 3 times daily starting 2 days prior to the expected onset of menstruation and continued for a total of 6 days. Headache activity was compared during the 3 months of recording prior to eletriptan therapy and 3 months with eletriptan perimenstrual prevention therapy. Results.— Three months of pretreatment prospective diaries were completed by 126 women. ICHD‐II menstrually related migraine was diagnosed in 74%, with pure MM in 7%. Among those women diagnosed with ICHD‐II MM, 61 completed at least 1 treatment month. Overall change in headache activity was a 46% decrease. The mean percentage of treated menses without migraine occurring during the 6 days of treatment was 71%. The percentage of subjects with 1, 2, and 3 migraine‐free menstrual periods (no migraines occurring 2 days before menses through the first 3 days of menstruation) with eletriptan, respectively, were 14%, 19%, and 53%. Among those subjects who remained headache‐free during the 6 days of eletriptan treatment, migraine occurred during the 3 days immediately after discontinuing eletriptan for 9%. Perimenstrual eletriptan was generally tolerated and no abnormalities were identified on the 6 th day of treatment using either blood pressure recording or electrocardiogram. Conclusions.— Among patients with prospectively identified MM, eletriptan 20 mg 3 times daily effectively reduced MM. A significant reduction in headache activity occurred for 53% of patients. ( Headache 2010;50:551‐562)